Chronic lung allograft dysfunction is a label for a wide range of clinical manifestations that all lead to the transplanted lung losing its normal function. There can be some variation in how CLAD ...

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. Food and Drug Administration (FDA) had approved another indication for its anti-PD-L1 immunotherapy Imfinzi (durvalumab) in lung cancer.

The test processes whole-slide images of non-small cell lung cancer tissue to provide a quantitative TROP2 score, which Roche says provides a level of precision beyond manual methods. TROP2 has ...